WW Stock Recent News
WW LATEST HEADLINES
WW International (WW) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.06 per share a year ago.
Fourth Quarter 2024 Financial Highlights Total End of Period Subscribers of 3.3 million, including 92 thousand End of Period Clinical Subscribers Revenues of $184.4 million; Subscription Revenues down 7.3% vs. prior year period, including Clinical Subscription Revenues of $20.5 million, up 57.9% vs.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) will release its results for the fourth quarter and full year 2024 ended December 28, 2024, after market close on Thursday, February 27, 2025.
The Wall Street Journal reported, citing unnamed sources, that WeightWatchers and the lender advisers recently entered into a confidentiality agreement.
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares soaring nearly 47%.
Shares of WW International Inc (WW, Financial) soared by 43.09% today due to the company's strategic move to expand its clinical weight management services. This expansion includes the introduction of compounded semaglutide, which offers a cost-effective and accessible alternative to popular medications like Ozempic and Wegovy, particularly during the current supply shortages.
WW International (WW, Financial) experienced a significant stock price increase, soaring 20.7% to $1.40. Early trading saw the stock rise as much as 46.5%.
Shares of WW International (WW), better known as WeightWatchers, jumped nearly 25% Tuesday when the dieting services company announced it is offering a copycat version of blockbuster weight-loss drugs.
“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Executive Tara Comonte in prepared remarks.
WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its weight-management programs.